Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SpringWorks Therapeutics, Inc.SWTX · Entity 15910 | General Counsel & Secretary | September 12, 2019 | September 12, 2019 |
| Veradermics, IncMANE · Entity 1907 | General Counsel | February 03, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SpringWorks Therapeutics, Inc.
Report date September 12, 2019 · Filed September 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,574 |
Reported balance
Holding disclosure · report date 2019-09-12 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 185,574 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2029-03-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-09-12 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: 25% of this option shall vest and become exercisable on March 19, 2020, with the remainder vesting in 36 equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2029-04-22 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-09-12 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: Vesting began to occur over the forty eight (48) month period following April 22, 2019 ("Vesting Commencement Date") in the following manner: The first vesting date ("First Vesting Date") was August 22, 2019, which was the 22nd day of the month occurring after the one year-anniversary of August 13, 2018. The amount of stock options that vested on the First Vesting Date was equal to the percentage of such forty eight (48) month period that has elapsed between the Vesting Commencement Date and the First Vesting Date. The remainder shall vest and become exercisable in equal monthly installments over the remaining months of such forty eight (48) month period on the monthly anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on March 19, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
F2: Vesting began to occur over the forty eight (48) month period following April 22, 2019 ("Vesting Commencement Date") in the following manner: The first vesting date ("First Vesting Date") was August 22, 2019, which was the 22nd day of the month occurring after the one year-anniversary of August 13, 2018. The amount of stock options that vested on the First Vesting Date was equal to the percentage of such forty eight (48) month period that has elapsed between the Vesting Commencement Date and the First Vesting Date. The remainder shall vest and become exercisable in equal monthly installments over the remaining months of such forty eight (48) month period on the monthly anniversary of the Vesting Commencement Date.
Veradermics, Inc
Report date February 03, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-02-03 | Direct | 144,401 |
Reported balance
After 2026-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-03 · Grant · Acquired 144,401 · Balance 144,401 F1: The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share, on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share, on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 5, 2026 19:02 UTC | Veradermics, Inc MANE · Entity 1907 | GrantStock Option (Right to Buy) · Derivative | 144,401 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001628280-26-005903 · wk-form4_1770336145.xml · derivative · entry 1 Greco Michael V. · CIK 0001786766 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,401 Underlying: Common Stock · 144,401 shares Expires 2036-02-03 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of the Issuer's common stock, par value $0.00001 per share, on February 3, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.